NEW YORK (Reuters Health)—Continued efforts are needed to increase the number of women and minorities in graduate medical education (GME) to ensure a diverse U.S. physician workforce, say the authors of a research letter published today. “Diversifying the physician workforce has been discussed as requisite to addressing health disparities and inequities. Minority physicians continue to…
Online Education for ARHP Members
In the past decade, there has been a clear demand for and a significant increase in online learning. This was clearly documented in the 2013 report, Changing Course: Ten Years of Tracking Online Education in the United States.1 The report finding demonstrated that 6.7 million students were taking at least one online course, a marked…
2016 ACR/ARHP Annual Meeting: Session & Study Group Proposals Welcome
Turn your great idea into a great meeting! Submit your session or study group proposal for the 2016 ACR/ARHP Annual Meeting, to be held Nov. 11–16, 2016, in Washington, D.C. We are looking for ideas that reflect clinical innovation and cutting-edge research, convey best practices, present evidence-based medicine and stimulate discussion to challenge mindsets. When developing your…
Rheumatology Research Foundation Funds Advance Investigator’s Career
William Robinson, MD, PhD, first became interested in rheumatology in medical school when he started working with a rheumatologist, as well as several other rheumatology mentors. After completing his residency, he joined the rheumatology fellowship program at Stanford University Medical Center, Palo Alto, Calif., where he earned support for his research from the Rheumatology Research…
The ACR’s Lupus Initiative Expands Training, Educational Resources
The Lupus Initiative (TLI) has been an emergent creation inside the American College of Rheumatology (ACR) for the past six years. In 2009, the Office of Minority Health and Office of Women’s Health (now called the Office of Health Disparities) solicited an application from the ACR to develop resources for educating non-rheumatologists, both in training…
7 Tips for New Rheumatology Fellows
About a year ago, I stuffed all my earthly belongings into my black Volkswagen Jetta and set out on a 10-hour interstate journey. I had just graduated from residency at the University of Kentucky and was headed westward, to Iowa City, for a fresh start as a rheumatology fellow. During the 10 hours I spent…
Maintaining Board Certification Has High Hidden Cost
NEW YORK (Reuters Health)—The American Board of Internal Medicine (ABIM) maintenance-of-certification (MOC) program could cost $5.7 billion in physicians’ time and fees over the next decade, according to a new model study. “We estimate that physicians will spend 33 million hours over 10 years to fulfill MOC requirements,” Dr. Dhruv S. Kazi from the University…
The ACR’s State-of-the-Art Clinical Symposium: Patients with Scleroderma, Lung Disease May Benefit from Aggressive Therapy
CHICAGO—Scleroderma patients with pulmonary arterial hypertension (PAH) might benefit from more aggressive therapy, an expert in the field said in a session on lung involvement in rheumatic diseases at the American College of Rheumatology’s 2015 State-of-the-Art Clinical Symposium in May. Newer trials—the SERAPHIN trial on macitentan, GRIPHON on selexipag, and AMBITION on an ambrisentan/tadalafil combination—show…
Rheumatologists on the Move, July 2015
Arthritis Center Renamed to Honor Ephraim P. Engleman, MD Ephraim P. Engleman, MD, has been on the faculty at the University of California, San Francisco (UCSF) since 1947, 10 years after he received his MD from Columbia University. The 104-year-old rheumatologist is currently the director of the Rosalind Russell/Ephraim P. Engleman Rheumatology Research Center, which…
The ACR’s State-of-the-Art Clinical Symposium: Experts Discuss Jakinibs, Osteoarthritis, Membranous Lupus Nephritis
CHICAGO—With the approval of the Jak inhibitors (i.e., jakinibs) tofacitinib and ruxolitinib—and others being investigated—rheumatologists need to arm themselves with an understanding of these drugs so they can think critically when evaluating them and deciding how to use them, said John O’Shea, MD, chief of the Molecular Immunology and Inflammation Branch of and scientific director…
- « Previous Page
- 1
- …
- 36
- 37
- 38
- 39
- 40
- …
- 74
- Next Page »